Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

Jared M Baeten,Thesla Palanee-Phillips,Elizabeth R Brown,Katie Schwartz,Lydia E Soto-Torres,Vaneshree Govender,Nyaradzo M Mgodi,Flavia Matovu Kiweewa,Gonasagrie Nair,Felix Mhlanga,Samantha Siva,Linda-Gail Bekker,Nitesha Jeenarain,Zakir Gaffoor,Francis Martinson,Bonus Makanani,Arendevi Pather,Logashvari Naidoo,Marla Husnik,Barbra A Richardson,Urvi M Parikh,John W Mellors,Mark A Marzinke,Craig W Hendrix,Ariane van der Straten,Gita Ramjee,Zvavahera M Chirenje,Clemensia Nakabiito, Taha E Taha,Judith Jones,Ashley Mayo,Rachel Scheckter, Jennifer Berthiaume,Edward Livant,Cindy Jacobson,Patrick Ndase, Rhonda White,Karen Patterson, Donna Germuga,Beth Galaska,Katherine Bunge,Devika Singh,Daniel W Szydlo,Elizabeth T Montgomery,Barbara S Mensch,Kristine Torjesen,Cynthia I Grossman,Nahida Chakhtoura,Annalene Nel,Zeda Rosenberg,Ian McGowan,Sharon Hillier

The New England journal of medicine（2016）

引用 771|浏览29

暂无评分

摘要

A monthly vaginal ring containing dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01617096 .).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要